Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

  • Harry P. Erba
  • , Hamid Sayar
  • , Mark Juckett
  • , Michael Lahn
  • , Valerie Andre
  • , Sophie Callies
  • , Shelly Schmidt
  • , Sunil Kadam
  • , John T. Brandt
  • , Dirk Van Bockstaele
  • , Michael Andreeff

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science